Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Increases By 317.4%

Xilio Therapeutics, Inc. (NASDAQ:XLO) saw a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 175,300 shares, a growth of 317.4% from the November 15th total of 42,000 shares. Based on an average trading volume of 246,400 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.9% of the company’s shares are sold short.

Xilio Therapeutics Trading Down 2.3 %

Shares of XLO stock opened at $1.04 on Thursday. Xilio Therapeutics has a twelve month low of $0.49 and a twelve month high of $1.93. The stock has a market capitalization of $45.72 million, a price-to-earnings ratio of -0.60 and a beta of -0.29. The stock has a fifty day simple moving average of $0.99 and a two-hundred day simple moving average of $0.93.

Institutional Investors Weigh In On Xilio Therapeutics

Several hedge funds have recently made changes to their positions in XLO. XTX Topco Ltd purchased a new stake in shares of Xilio Therapeutics in the 2nd quarter worth $32,000. Geode Capital Management LLC lifted its holdings in shares of Xilio Therapeutics by 85.0% in the 3rd quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock worth $266,000 after buying an additional 155,337 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Xilio Therapeutics by 18.3% during the 2nd quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock worth $280,000 after purchasing an additional 45,554 shares during the last quarter. 54.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Raymond James cut their price objective on Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.